Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/208412
Title: | Reversions of QuantiFERON-TB Gold Plus in tuberculosis contact investigation: A prospective multicentre cohort study |
Author: | García Gasalla, Mercedes Pérez-Recio, Sandra Grijota Camino, Maria D. Anibarro, Luis Rabuñal Rey, Ramón Sabrià, Josefina Gijón-Vidaurreta, Paloma Pomar, Virginia Domínguez-Castellano, Ángel Trigo, Matilde Santos, María Jesús Cebollero, Alba Rodríguez, Sara Moga, Esther Penas-Truque, Anton Martos, Carmen Ruiz-Serrano, M.Jesús García de Cara, Erika Inés Alcaide Fernández de Vega, Fernando Santín Cerezales, Miguel |
Keywords: | Tuberculosi Medicina preventiva Adults Tuberculosis Preventive medicine Adulthood |
Issue Date: | 30-Aug-2023 |
Publisher: | Public Library of Science (PLoS) |
Abstract: | Background: Interferon-y Release Assays (IGRA) reversions have been reported in different clinical scenarios for the diagnosis of tuberculosis (TB) infection. This study aimed to determine the rate of QuantiFERON-TB Gold Plus (QFT-Plus) reversions during contact investigation as a potential strategy to reduce the number of preventive treatments. Methods: Prospective, multicentre cohort study of immunocompetent adult contacts of patients with pulmonary TB tested with QFT-Plus. Contacts with an initial positive QFT-Plus (QFT-i) underwent a second test within 4 weeks (QFT-1), and if negative, underwent a repeat test 4 weeks later (QFT-2). Based on the QFT-2 result, we classified cases as sustained reversion if they remained negative and as temporary reversion if they turned positive. Results: We included 415 contacts, of whom 96 (23.1%) had an initial positive test (QFT-i). Following this, 10 had negative QFT-1 results and 4 (4.2%) of these persisted with a negative result in the QFT-2 (sustained reversions). All four sustained reversions occurred in contacts with IFN-γ concentrations between ≥0.35 and ≤0.99 IU•mL-1 in one or both QFT-i tubes. Conclusion: In this study, TB contact investigations rarely reveal QFT-Plus reversion. These results do not support retesting cases with an initial positive result to reduce the number of preventive treatments. |
Note: | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0285917 |
It is part of: | PLoS One, 2023, vol. 18, num.8 |
URI: | http://hdl.handle.net/2445/208412 |
Related resource: | https://doi.org/10.1371/journal.pone.0285917 |
ISSN: | 1932-6203 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
842416.pdf | 572.9 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License